FDA FLOATS LEGISLATIVE AGENDA ON CAPITOL HILL; AGENCY SEEKS REDEFINITION OF CLASS II AS "SAFETY AND PERFORMANCE" CATEGORY, DEEMPHASIZING SUBSTANTIAL EQUIVALENCE
This article was originally published in The Gray Sheet
An FDA "wish list" of device legislative concepts seeks to redefine Class II as a category focused on "safety and performance" rather than "substantial equivalence."
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.